A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.

The main questions it aims to answer are:

What is the the safe and effective dose of CRB-701 when used alone? What cancers can be treated effectively with CRB-701?

Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701 on its own. They will have blood tests and other assessments to measure whether CRB-701 will have CT or MRI scans to measure the effect on tumors.
- EligibilityCriteria: Inclusion Criteria:  Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed following at least one line of therapy or have no other standard therapy with proven clinical benefit.  Exclusion Criteria:  Active of uncontrolled CNS metastases History of solid tumors other than the diseases under study History of and/or current cardiovascular events or conditions in the previous 6 months Pre-existing >/= Grade 2 neuropathy Hemoglobin A1C (HbA1C) >/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy Active ocular disease at baseline Chronic severe liver disease or live cirrhosis Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study Other significant cormorbidities. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult